Royalty Pharma
RPRX
RPRX
198 hedge funds and large institutions have $11.4B invested in Royalty Pharma in 2020 Q4 according to their latest regulatory filings, with 93 funds opening new positions, 70 increasing their positions, 24 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
48% more funds holding
Funds holding: 134 → 198 (+64)
15.77% more ownership
Funds ownership: 43.53% → 59.3% (+16%)
54% less call options, than puts
Call options by funds: $18.1M | Put options by funds: $39.4M
Holders
198
Holding in Top 10
10
Calls
$18.1M
Puts
$39.4M
Top Buyers
| 1 | +$722M | |
| 2 | +$338M | |
| 3 | +$304M | |
| 4 |
BlackRock
New York
|
+$266M |
| 5 |
CCM
CAAS Capital Management
New York
|
+$180M |
Top Sellers
| 1 | -$365M | |
| 2 | -$251M | |
| 3 | -$45.8M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$31.1M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$17M |